A Phase 1, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a Single Subcutaneous Administration of SHR-2173 in Healthy Participants
Latest Information Update: 27 Feb 2026
At a glance
- Drugs SHR 2173 (Primary)
- Indications Immunological disorders
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Atridia
Most Recent Events
- 11 Feb 2026 New trial record